PURPOSE: Preclinical positron emission tomography studies are important to follow disease progression and develop new pharmacological agents. We investigated whether kinetic modeling of 5-HT2A tracer [(11)C]MDL 100907 is possible in rats. PROCEDURES AND RESULTS: Kinetic modeling with either metabolite-corrected plasma curve or with the cerebellum as a reference tissue resulted in a good correlation of nondisplaceable binding potential (BPND) calculated from a two-tissue compartment model (2TCM) or different reference tissue models. Injecting the tracer by a slower bolus decreases the variation in 2TCM outcome parameters and results in a good correlation between k3/k4 and the other models. Application of 0.2 mg/kg cold MDL 100907 resulted in almost complete occupancy of 5-HT2A receptors. CONCLUSIONS: A reference tissue model can be used for [(11)C]MDL kinetic modeling in rats, which is preferable in pharmacological or longitudinal studies.
PURPOSE: Preclinical positron emission tomography studies are important to follow disease progression and develop new pharmacological agents. We investigated whether kinetic modeling of 5-HT2A tracer [(11)C]MDL 100907 is possible in rats. PROCEDURES AND RESULTS: Kinetic modeling with either metabolite-corrected plasma curve or with the cerebellum as a reference tissue resulted in a good correlation of nondisplaceable binding potential (BPND) calculated from a two-tissue compartment model (2TCM) or different reference tissue models. Injecting the tracer by a slower bolus decreases the variation in 2TCM outcome parameters and results in a good correlation between k3/k4 and the other models. Application of 0.2 mg/kg cold MDL 100907 resulted in almost complete occupancy of 5-HT2A receptors. CONCLUSIONS: A reference tissue model can be used for [(11)C]MDL kinetic modeling in rats, which is preferable in pharmacological or longitudinal studies.
Authors: Philipp T Meyer; Zubin Bhagwagar; Philip J Cowen; Vincent J Cunningham; Paul M Grasby; Rainer Hinz Journal: Neuroimage Date: 2010-01-18 Impact factor: 6.556
Authors: Vincent J Cunningham; Eugenii A Rabiner; Mark Slifstein; Marc Laruelle; Roger N Gunn Journal: J Cereb Blood Flow Metab Date: 2009-09-09 Impact factor: 6.200
Authors: Anniek K D Visser; Aren van Waarde; Antoon T M Willemsen; Fokko J Bosker; Paul G M Luiten; Johan A den Boer; Ido P Kema; Rudi A J O Dierckx Journal: Eur J Nucl Med Mol Imaging Date: 2010-11-27 Impact factor: 9.236
Authors: Petra Schweinhardt; Peter Fransson; Lars Olson; Christian Spenger; Jesper L R Andersson Journal: J Neurosci Methods Date: 2003-10-30 Impact factor: 2.390
Authors: Javad Khodaii; Mostafa Araj-Khodaei; Manouchehr S Vafaee; Dean F Wong; Albert Gjedde Journal: J Nucl Med Date: 2021-06-04 Impact factor: 10.057
Authors: Kristoffer Sahlholm; Jurgen W A Sijbesma; Bram Maas; Chantal Kwizera; Daniel Marcellino; Nisha K Ramakrishnan; Rudi A J O Dierckx; Philip H Elsinga; Aren van Waarde Journal: Psychopharmacology (Berl) Date: 2015-07-11 Impact factor: 4.530